Literature DB >> 16723156

High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse.

Dagmara M Mirowska-Guzel1, Katarzyna Kurowska, Janusz Skierski, Mirosława Koronkiewicz, Wojciech Wicha, Jadwiga Kruszewska, Andrzej Czlonkowski, Anna Czlonkowska.   

Abstract

The aim of our study was to determine whether high doses of intravenous methylprednisolone have significant impact on immune parameters during the multiple sclerosis (MS) exacerbations. Peripheral blood of 32 MS patients was evaluated, using two-color flow cytometry before glucocorticosteroids and after 7 days from starting therapy. Significant increase of B cells, decrease of NK cells and monocytes producing IL-8 were observed after treatment. IL-8 is one of the cytokines responsible for blood-brain-barrier disruption and migration of immune cells to the central nervous system; in this aspect, explaining glucocorticosteroid effects during MS exacerbations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723156     DOI: 10.1016/j.jneuroim.2006.03.024

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.

Authors:  D Kempuraj; M Tagen; B P Iliopoulou; A Clemons; M Vasiadi; W Boucher; M House; A Wolfberg; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

2.  Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study.

Authors:  Z Matejčíková; J Mareš; H Přikrylová Vranová; J Klosová; V Sládková; J Doláková; J Zapletalová; P Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2014-06-04       Impact factor: 3.575

Review 3.  Cytokine Therapies in Neurological Disease.

Authors:  Shila Azodi; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 4.  B cells: no longer the nondominant arm of multiple sclerosis.

Authors:  Eric C Klawiter; Anne H Cross
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 6.030

Review 5.  Glucocorticoids and endothelial cell barrier function.

Authors:  Ellaine Salvador; Sergey Shityakov; Carola Förster
Journal:  Cell Tissue Res       Date:  2013-12-19       Impact factor: 5.249

6.  Glucocorticoid Therapy of Multiple Sclerosis Patients Induces Anti-inflammatory Polarization and Increased Chemotaxis of Monocytes.

Authors:  Henrike J Fischer; Tobias L K Finck; Hannah L Pellkofer; Holger M Reichardt; Fred Lühder
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 7.  The role of NK and NKT cells in the pathogenesis and improvement of multiple sclerosis following disease-modifying therapies.

Authors:  Alireza Ahmadi; Zahra Fallah Vastani; Mahdi Abounoori; Mahdieh Azizi; Alireza Labani-Motlagh; Sajad Mami; Sanaz Mami
Journal:  Health Sci Rep       Date:  2022-01-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.